References of "Caers, Jo"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailGalectin expression in the multiple myeloma microenvironment
Muller, Joséphine ULg; CAERS, Jo ULg; Binsfeld, Marilène ULg et al

in Belgian Journal of Hematology (2014)

Detailed reference viewed: 8 (1 ULg)
Full Text
See detailEstablishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation.
Binsfeld, Marilène ULg; BEGUIN, Yves ULg; Belle, Ludovic et al

in Belgian Journal of Hematology (2014)

Detailed reference viewed: 4 (0 ULg)
Full Text
See detailMultiple myeloma cells instruct myeloid-derived suppressor cells to release pro-angiogenic cytokines
Binsfeld, Marilène ULg; Heusschen, Roy ULg; Lamour, Virginie et al

in Belgian Journal of Hematology (2014)

Detailed reference viewed: 12 (2 ULg)
Full Text
Peer Reviewed
See detailLe myélome multiple asymptomatique : le paysage thérapeutique change
CAERS, Jo ULg; BEGUIN, Yves ULg

in Oncol. Hematol. (2014), 8

Le myélome multiple est le deuxième cancer hématologique en termes de fréquence avec plus de 700 nouveaux cas chaque année en Belgique. Le myélome asymptomatique, ou smoldering mye/omo, est un stade ... [more ▼]

Le myélome multiple est le deuxième cancer hématologique en termes de fréquence avec plus de 700 nouveaux cas chaque année en Belgique. Le myélome asymptomatique, ou smoldering mye/omo, est un stade précurseur du myélome multiple. En moyenne, les patients présentant un myélome asymptomatique ont un risque annuel de progression en myélome déclaré de 10%. Différents facteul"s ont été combinés dans des modélisations pronostiques: le rapport des chaînes légères, les anomalies radiologiques, la présence d'une gammapathie évolutive et l'infiltration médullaire > 60% ont récemment été identifiés comme facteurs prédictifs d'une progression précoce pour lesquels certains auteurs évoquent la mise en roùte d'un traitement anti-myélome. Cette stratégie thérapeutique précoce a démontré son efficacité dans une étude randomisée qui comparait un traitement par lénalidornide et dexaméthasone avec une approche attentiste chez des patients à risque. [less ▲]

Detailed reference viewed: 24 (0 ULg)
Full Text
Peer Reviewed
See detailDiagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physicians.
CAERS, Jo ULg; Vekemans, Marie-Christiane; Bries, Greet et al

in Annals of Medicine (2013), 45

The prevalence of monoclonal gammopathy of undetermined significance (MGUS) is generally estimated at 3.4% in the general population over 50 years, and its incidence increases with age. MGUS represents a ... [more ▼]

The prevalence of monoclonal gammopathy of undetermined significance (MGUS) is generally estimated at 3.4% in the general population over 50 years, and its incidence increases with age. MGUS represents a preneoplastic entity that can transform into multiple myeloma or other lymphoproliferative disorders. The risk of malignant transformation is estimated at 1% per year and persists over time. Predictors of malignant transformation have been identified such as the heavy chain isotype, the monoclonal component level, increasing levels of M-protein during the first years of follow-up, bone marrow plasmocytosis, dosage of serum free light chains, the presence of immunophenotypic abnormal plasma cells, aneuploidy and the presence of circulating plasma cells. Prognostic scores that combine certain of these factors have been proposed and allow the identification of high-risk patients. Their use could assist in tailoring the care for each patient, based on his/her risk profile. [less ▲]

Detailed reference viewed: 47 (7 ULg)
Full Text
Peer Reviewed
See detailPlasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.
Fernández de Larrea, C; Kyle, RA; Durie, BG et al

in Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (2013), 27(4), 780-91

Detailed reference viewed: 16 (1 ULg)
Full Text
Peer Reviewed
See detailA novel mutation in the CUB sequence of matriptase-2 (TMPRSS6) is implicated in iron-resistant iron deficiency anaemia (IRIDA).
JASPERS, Aurélie ULg; CAERS, Jo ULg; LE GAC, Gerald et al

in British Journal of Haematology (2013), 160(4), 564-565

Detailed reference viewed: 27 (12 ULg)
Full Text
Peer Reviewed
See detailImage of the month: Hairy kidneys
Cornet, G; GRAYET, Benjamin ULg; Godon, A et al

in Revue Médicale de Liège (2013), 68(1), 4-5

Detailed reference viewed: 25 (0 ULg)
Full Text
Peer Reviewed
See detailGammapathies monoclonales de signification indéterminée
Vekemans, Marie-Christiane; CAERS, Jo ULg; Doyen, Chantal et al

in Louvain Medical (2013), 132(2), 51-62

Detailed reference viewed: 20 (4 ULg)
Full Text
Peer Reviewed
See detailUnexplained cardiac failure leading to the identification of a Belgian family affected by hereditary amyloidosis.
DE PASQUAL, Aurelie ULg; BIESSAUX, Yves ULg; Blettard, Noelle et al

in Acta Clinica Belgica (2013), 68(4), 303-305

Detailed reference viewed: 22 (8 ULg)
Peer Reviewed
See detailErdheim-Chester Disease : A Monocentric Series Of 96 Patients
Haroche, Julien; Arnaud, Laurent; Cohen-Aubart, Fleur et al

Poster (2013)

Detailed reference viewed: 13 (1 ULg)
Full Text
Peer Reviewed
See detailBone mass of the calvarium
SIMONI, Paolo ULg; STULKO, Jennifer ULg; BEN MUSTAPHA, Selma ULg et al

in Skeletal Radiology (2013), 42

Detailed reference viewed: 24 (4 ULg)